Insr Phenotype Annotations

Mammalian Phenotype Ontology Annotations
Query Results - Summary

Symbol
Name
ID

Insr
insulin receptor
MGI:96575

97 phenotypes from 9 alleles in 20 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Insr^m1Btlr/Insr^m1Btlr C57BL/6J-Insr^m1Btlr	increased susceptibility to induced colitis	J:267534
Insr^M2Btlr/Insr^M2Btlr C57BL/6J-Insr^M2Btlr	increased insulin secretion	J:267535
Insr^Rgsc294/Insr⁺ involves: C57BL/6JJcl * DBA/2JJcl	hyperglycemia	J:133634
	increased circulating insulin level	J:133634
	increased urine glucose level	J:133634
Insr^Rgsc824/Insr⁺ involves: C57BL/6JJcl * DBA/2JJcl	hyperglycemia	J:133634
	increased circulating insulin level	J:133634
	increased glycosylated hemoglobin level	J:133634
	increased urine glucose level	J:133634
Insr^Rgsc1777/Insr⁺ involves: C3H * C57BL/6JJcl	hyperglycemia	J:133634
Insr^Rgsc1777/Insr⁺ involves: C3H * C57BL/6JJcl	increased circulating insulin level	J:133634
Insr^tm1Dac/Insr⁺ B6.129S4-Insr^tm1Dac/J	increased circulating insulin level	J:246319
	increased pancreatic beta cell mass	J:246319
	insulin resistance	J:246319
Insr^tm1Dac/Insr⁺ involves: 129 * C57BL/6J	increased circulating insulin level	J:135659
	increased pancreatic beta cell mass	J:135659
	insulin resistance	J:135659
Insr^tm1Dac/Insr⁺ involves: C3H/HeH * C57BL/6	increased circulating insulin level	J:141688
Insr^tm1Dac/Insr⁺ involves: C3H/HeH * C57BL/6	increased insulin secretion	J:141688
Insr^tm1Dac/Insr^tm1Dac involves: 129S4/SvJae * C57BL/6	abnormal glucose homeostasis	J:79560
	hepatic steatosis	J:33408
	hyperglycemia	J:33408
	increased circulating insulin level	J:33408
	ketoaciduria	J:33408
	postnatal lethality, complete penetrance	J:33408
Insr^tm1Jja/Insr^tm1Jja involves: 129S2/SvPas * C57BL/6 * DBA/2	decreased body weight	J:32538
	decreased liver glycogen level	J:32538
	decreased total body fat amount	J:80773
	enlarged liver	J:32538
	hepatic steatosis	J:32538, J:80773
	hyperglycemia	J:32538
	increased circulating free fatty acids level	J:32538
	increased circulating insulin level	J:32538
	increased circulating triglyceride level	J:32538
	increased urine glucose level	J:32538
	ketoaciduria	J:32538, J:80773
	postnatal lethality	J:80773
	postnatal lethality, complete penetrance	J:32538
	skeletal muscle hypotrophy	J:32538
Insr^tm1Khn/Insr^tm1Dac Tg(Ckmm-cre)5Khn/0 involves: 129S4/SvJae * C57BL/6J * FVB	hyperglycemia	J:51266
	increased circulating insulin level	J:51266
Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ involves: 129S4/SvJae * C57BL/6 * C57BL/6J	abnormal enzyme/coenzyme activity	J:234643
	abnormal hepatocyte physiology	J:234643
	abnormal liver morphology	J:234643
	abnormal liver physiology	J:234643
	decreased liver glycogen level	J:234643
	hyperglycemia	J:234643
	impaired glucose tolerance	J:234643
	increased circulating insulin level	J:234643
	insulin resistance	J:234643
Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ involves: 129S4/SvJae * C57BL/6 * DBA/2	decreased circulating glucose level	J:121640
	hyperglycemia	J:121640
	impaired glucose tolerance	J:121640
	increased circulating insulin level	J:121640
	increased pancreatic beta cell mass	J:121640
	insulin resistance	J:121640
Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ involves: 129S4/SvJae * C57BL/6J * DBA/2 * FVB	abnormal circulating serum albumin level	J:63878
	abnormal glucose homeostasis	J:63878
	abnormal hepatocyte morphology	J:63878
	abnormal insulin clearance	J:63878
	abnormal lipid homeostasis	J:63878
	abnormal liver morphology	J:63878
	abnormal liver physiology	J:63878
	decreased circulating free fatty acids level	J:63878
	decreased circulating triglyceride level	J:63878
	enlarged gallbladder	J:63878
	hyperglycemia	J:63878
	impaired glucose tolerance	J:63878
	increased bile salt level	J:92861
	increased circulating alkaline phosphatase level	J:63878
	increased circulating aspartate transaminase level	J:63878
	increased circulating insulin level	J:63878
	increased insulin secretion	J:63878
	increased mitochondrial size	J:63878
	increased pancreatic beta cell mass	J:63878, J:92861
	insulin resistance	J:63878
	pancreatic islet hyperplasia	J:92861
	postnatal growth retardation	J:63878
	small liver	J:63878
Insr^tm1Khn/Insr^tm1Khn Speer6-ps1^{Tg(Alb-cre)21Mgn}/Speer6-ps1⁺ Tg(Ins2-cre)25Mgn/0 involves: 129S4/SvJae * C57BL/6 * DBA/2	decreased body weight	J:121640
	decreased insulin secretion	J:121640
	normal digestive/alimentary phenotype	J:121640
	hyperglycemia	J:121640
	impaired glucose tolerance	J:121640
	increased circulating insulin level	J:121640
	insulin resistance	J:121640
	polydipsia	J:121640
	polyuria	J:121640
	premature death	J:121640
Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0 involves: 129S4/SvJae * C57BL/6 * FVB	normal cardiovascular system phenotype	J:118987
	normal growth/size/body region phenotype	J:118987
	normal homeostasis/metabolism phenotype	J:118987
Insr^tm1Khn/Insr^tm1Khn Tg(Ckmm-cre)5Khn/0 involves: 129S4/SvJae * C57BL/6J * FVB	abnormal fat pad morphology	J:51266
	normal homeostasis/metabolism phenotype	J:51266
	increased fatty acids level	J:51266
	increased triglyceride level	J:51266
Insr^tm1Khn/Insr^tm1Khn Tg(Ins2-cre)25Mgn/0 involves: 129S4/SvJae * C57BL/6 * DBA/2	decreased insulin secretion	J:121640
	decreased pancreatic beta cell mass	J:121640
	hyperglycemia	J:121640
	impaired glucose tolerance	J:121640
	increased susceptibility to induced morbidity/mortality	J:121640
	premature death	J:121640
Insr^tm1Khn/Insr^tm1Khn Tg(Myhca-cre)1Abel/0 involves: 129S4/SvJae * FVB	abnormal cardiac muscle cell glucose uptake	J:75348
	abnormal cardiovascular system physiology	J:75348
	abnormal glucose homeostasis	J:75348
	abnormal heart development	J:75348
	abnormal lipid homeostasis	J:75348
	decreased cardiac muscle cell glucose uptake	J:75348
	decreased cardiac output	J:75348
	decreased coronary flow rate	J:75348
	decreased heart left ventricle muscle contractility	J:75348
	decreased heart left ventricle posterior wall thickness	J:75348
	decreased heart left ventricle weight	J:75348
	decreased myocardial fiber size	J:75348
	increased cardiac muscle cell glucose uptake	J:75348
	increased cardiac muscle glycogen level	J:75348
	small heart	J:75348
Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0 involves: 129S4/SvJae * C57BL/6 * SJL	abnormal glucose homeostasis	J:109359
Insr^tm1Khn/Insr^tm1Khn Tg(Nes-cre)1Kln/0 involves: 129S4/SvJae * C57BL/6J * SJL	abnormal seminiferous tubule morphology	J:64790
	abnormal spermatogenesis	J:64790
	decreased circulating luteinizing hormone level	J:64790
	decreased corpora lutea number	J:64790
	decreased Leydig cell number	J:64790
	decreased tertiary ovarian follicle number	J:64790
	increased body weight	J:64790
	increased circulating insulin level	J:64790
	increased circulating leptin level	J:64790
	increased circulating triglyceride level	J:64790
	increased white adipose tissue amount	J:64790
	insulin resistance	J:64790
	normal nervous system phenotype	J:64790
	oligozoospermia	J:64790
	polyphagia	J:64790
	reduced male fertility	J:64790
Insr^tm1Khn/Insr^tm1Khn Tg(Pdgfrb-cre)#Rha/0 involves: 129S4/SvJae * C57BL/6J	abnormal retina blood vessel morphology	J:327000
	abnormal retina blood vessel pattern	J:327000
	abnormal retina vasculature morphology	J:327000
	abnormal vascular plexus formation	J:327000
	increased circulating insulin level	J:327000
Insr^tm1Khn/Insr^tm1Khn Tg(Slc2a4-cre)546Dac/0 involves: 129S4/SvJaeSor * C57BL/6 * FVB	abnormal brown adipose tissue morphology	J:169404
	abnormal circadian feeding behavior	J:169404
	abnormal epididymal fat pad morphology	J:169404
	abnormal glucose homeostasis	J:169404
	abnormal lean body mass	J:169404
	abnormal pancreatic beta cell morphology	J:169404
	abnormal pancreatic islet morphology	J:169404
	decreased body weight	J:169404
	decreased liver glycogen level	J:169404
	decreased pancreatic beta cell number	J:169404
	hepatic steatosis	J:169404
	normal homeostasis/metabolism phenotype	J:169404
	hyperglycemia	J:169404
	impaired glucose tolerance	J:169404
	increased brown fat cell lipid droplet size	J:169404
	increased circulating free fatty acids level	J:169404
	increased circulating glucose level	J:169404
	increased circulating insulin level	J:169404
	increased oxygen consumption	J:169404
	insulin resistance	J:169404
	postnatal growth retardation	J:169404
Insr^tm1Shs/Insr⁺ involves: C57BL/6CrSlc	abnormal liver physiology	J:98723
	decreased susceptibility to induced morbidity/mortality	J:98723
	decreased susceptibility to xenobiotic induced morbidity/mortality	J:98723
	decreased total body fat amount	J:98723
	hyperglycemia	J:98723
	impaired glucose tolerance	J:98723
	increased circulating insulin level	J:98723
	increased insulin sensitivity	J:98723
	insulin resistance	J:98723
Insr^tm1Shs/Insr^tm1Shs involves: C57BL/6CrSlc	ketoacidosis	J:98723
	postnatal growth retardation	J:98723
	postnatal lethality, complete penetrance	J:98723
Gt(ROSA)26Sor/Gt(ROSA)26Sor⁺ involves: C57BL/6	hyperglycemia	J:151686
Gt(ROSA)26Sor/Gt(ROSA)26Sor⁺ involves: C57BL/6	insulin resistance	J:151686

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 11/19/2024 MGI 6.24